Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 21-10-2021 | Myelodysplastic Syndrome | Original Article – Clinical Oncology

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

Authors: Samantha O‘Hagan Henderson, Jochen J. Frietsch, Inken Hilgendorf, Andreas Hochhaus, Claus-Henning Köhne, Jochen Casper

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2022

Abstract

Purpose

Treosulfan and fludarabine (Treo/Flu) were successfully introduced into toxicity-reduced conditioning for SCT. However, the risk of post-SCT relapse remains a matter of concern. We report the results of a novel individual treatment approach with Treo/Flu and cytarabine (Treo/Flu/AraC) conditioning prior to allogeneic SCT in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN).

Methods

Seventy-seven patients (median age 54 years) at high risk of disease relapse due to unfavorable cytogenetics or failure to achieve complete remission prior to SCT were included. Median follow-up was 3.2 years.

Results

The 1-, 2- and 3-year RFS rates were 49.4%, 41.7%, and 37.6% and OS rates were 59.3%, 49.3%, and 45.4%, respectively. Cumulative incidence of NRM was 10% at 100 days, 18.8% at 1 year and 20.1% at 2 years. The cumulative incidence of relapse increased from 31% at 1 year to 38.5% after 3 years. The cumulative incidences of engraftment, chimerism, graft-versus-host disease (GvHD) and toxicities were acceptable and comparable with similar patients conditioned with Treo/Flu or FLAMSA-RIC.

Conclusion

In conclusion, Treo/Flu/AraC provides tolerable, feasible, and effective conditioning for patients with AML, MDS or MPN, even in advanced disease states. The incidence of NRM and relapse is acceptable in this heavily pre-treated population with high-risk disease. Future research will aim to confirm these initial findings and include a larger number of participants in a prospective trial.

Available only for authorised users

Arai Y, Aoki K, Takeda J, Kondo T, Eto T, Ota S et al (2015) Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy. J Hematol Oncol 8(1):102. https://doi.org/10.1186/s13045-015-0201-xCrossRefPubMedPubMedCentral

Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M et al (2008) Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 83(9):717–720. https://doi.org/10.1002/ajh.21240CrossRefPubMed

Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35(3):233–241. https://doi.org/10.1038/sj.bmt.1704784CrossRefPubMed

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P et al (2020) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 7(1):e28–e39. https://doi.org/10.1016/S2352-3026(19)30157-7CrossRefPubMed

Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R (2016) Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 51(2):232–240. https://doi.org/10.1038/bmt.2015.238CrossRefPubMed

Capizzi RL (1996) Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs 14(3):249–256. https://doi.org/10.1007/BF00194527CrossRefPubMed

Casper J, Freund M (2004) Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 42(11):661–662. https://doi.org/10.5414/cpp42661CrossRefPubMed

Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al (2004a) Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2):725–731. https://doi.org/10.1182/blood-2002-11-3615CrossRefPubMed

Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H et al (2004b) Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol 83(Suppl 1):S70–S71. https://doi.org/10.1007/s00277-004-0850-2CrossRefPubMed

Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28(20):3344–3351. https://doi.org/10.1200/JCO.2009.23.3429CrossRefPubMed

Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T et al (2012) Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transplant 47(9):1171–1177. https://doi.org/10.1038/bmt.2011.242CrossRefPubMed

Corbacioglu S, Jabbour EJ, Mohty M (2019) Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant 25(7):1271–1280. https://doi.org/10.1016/j.bbmt.2019.02.018CrossRefPubMed

Deeg HJ, Stevens EA, Salit RB, Ermoian RP, Fang M, Gyurkocza B et al (2018) Transplant conditioning with treosulfan/fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 24(5):956–963. https://doi.org/10.1016/j.bbmt.2017.12.785CrossRefPubMed

Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225–230PubMed

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196CrossRefPubMedPubMedCentral

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956. https://doi.org/10.1016/j.bbmt.2005.09.004CrossRefPubMed

Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41(2):93–103. https://doi.org/10.2165/00003088-200241020-00002CrossRefPubMed

Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116–124. https://doi.org/10.1200/JCO.1993.11.1.116CrossRefPubMed

Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A et al (2014) Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 20(4):549–555. https://doi.org/10.1016/j.bbmt.2014.01.009CrossRefPubMedPubMedCentral

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant 22(1):4–10. https://doi.org/10.1016/j.bbmt.2015.09.001CrossRefPubMed

Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagacli AH, Pichlmeier U et al (2011) Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplant 46(4):502–509. https://doi.org/10.1038/bmt.2010.153CrossRefPubMed

Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphanet J Rare Dis 2(1):35. https://doi.org/10.1186/1750-1172-2-35CrossRefPubMedPubMedCentral

Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M et al (2013) Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol 92(10):1397–1403. https://doi.org/10.1007/s00277-013-1790-5CrossRefPubMed

Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37(4):339–344. https://doi.org/10.1038/sj.bmt.1705259CrossRefPubMed

Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C et al (2006) Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91(7):935–940PubMed

Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J et al (2017) sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the acute leukemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 23(2):278–284. https://doi.org/10.1016/j.bbmt.2016.11.002CrossRefPubMed

McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R et al (2012) Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. Int J Hematol 96(6):743–747. https://doi.org/10.1007/s12185-012-1192-9CrossRefPubMed

Michallet M, Sobh M, Milpied N, Bay JO, Furst S, Harousseau JL et al (2012) Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. Ann Hematol 91(8):1289–1297. https://doi.org/10.1007/s00277-012-1429-yCrossRefPubMed

Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaaoui RE, Wehner S et al (2008) Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 62(5):821–830. https://doi.org/10.1007/s00280-007-0669-3CrossRefPubMed

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A et al (2017) Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the acute leukemia working party of the european society for blood and marrow transplantation. Cancer 123(14):2671–2679. https://doi.org/10.1002/cncr.30646CrossRefPubMed

Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J et al (2013) Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 48(4):537–543. https://doi.org/10.1038/bmt.2012.239CrossRefPubMed

Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ et al (2015) Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia 29(8):1754–1762. https://doi.org/10.1038/leu.2015.75CrossRefPubMedPubMedCentral

Patel H, Molina A, Nikanjam M, Schiller GJ (2016) Risk factors for relapse following allogeneic transplant for acute myeloid leukemia in the UCLA patient population. Blood 128(22):5855. https://doi.org/10.1182/blood.V128.22.5855.5855CrossRef

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M et al (2016) Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol 142(1):317–324. https://doi.org/10.1007/s00432-015-2050-yCrossRefPubMed

Remberger M, Torlen J, Serafi IE, Garming-Legert K, Bjorklund A, Ljungman P et al (2017) Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. Int J Hematol 106(4):471–475. https://doi.org/10.1007/s12185-017-2320-3CrossRefPubMed

Rodriguez-Arboli E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J et al (2020) FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant 26(11):2165–2173. https://doi.org/10.1016/j.bbmt.2020.07.020CrossRefPubMed

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M et al (2011) Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica 96(9):1344–1350. https://doi.org/10.3324/haematol.2011.043810CrossRefPubMedPubMedCentral

Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J et al (2014) Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 20(1):135–138. https://doi.org/10.1016/j.bbmt.2013.10.014CrossRefPubMed

Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346. https://doi.org/10.1016/0197-2456(96)00075-xCrossRefPubMed

Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6(11):4209–4216PubMed

Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H et al (2007) Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 39(7):389–396. https://doi.org/10.1038/sj.bmt.1705605CrossRefPubMed

Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA (2013) Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol 92(10):1389–1395. https://doi.org/10.1007/s00277-013-1774-5CrossRefPubMed

Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL et al (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 35(11):1154–1161. https://doi.org/10.1200/JCO.2016.70.7091CrossRefPubMedPubMedCentral

Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387. https://doi.org/10.1038/sj.bmt.1705727CrossRefPubMed

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A et al (2019) Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant 54(4):531–539. https://doi.org/10.1038/s41409-018-0288-0CrossRefPubMed

Shimoni A, Rand A, Shem-Tov N, Hardan I, Volchek Y, Yerushalmi R et al (2010) Fludarabine and treosulfan conditioning for allogeneic stem-cell transplantation; a dose-intense regimen with limited toxicity. Blood 116(21):3473. https://doi.org/10.1182/blood.V116.21.3473.3473CrossRef

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J et al (2016) Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol 9(1):118. https://doi.org/10.1186/s13045-016-0347-1CrossRefPubMedPubMedCentral

Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G et al (2018) Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of european society for blood and marrow transplantation. Biol Blood Marrow Transplant 24(4):751–757. https://doi.org/10.1016/j.bbmt.2017.12.776CrossRefPubMed

Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M et al (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34(1):115–121. https://doi.org/10.1016/j.exphem.2005.09.015CrossRefPubMed

Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl J Med 341(1):14–21. https://doi.org/10.1056/NEJM199907013410103CrossRefPubMed

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. https://doi.org/10.1182/blood-2005-05-2004CrossRefPubMedPubMedCentral

Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M et al (2012) Impact of graft-versus-host disease on relapse after allogeneic hematopoietic stem cell transplantation, an EBMT Megafile study. Blood 120(21):469. https://doi.org/10.1182/blood.V120.21.469.469CrossRef

Title: Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
Authors: Samantha O‘Hagan Henderson
Jochen J. Frietsch
Inken Hilgendorf
Andreas Hochhaus
Claus-Henning Köhne
Jochen Casper
Publication date: 21-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Conditioning
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2022
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03836-8

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

ERS Congress 2024

Springer Medicine

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

Abstract

Purpose

Methods

Results

Conclusion

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2022

Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?

Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial

Protein expression of prognostic genes in primary melanoma and benign nevi

Natural history of Von Hippel–Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study

Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials